Literature DB >> 23728822

Latent tuberculosis infection: screening and treatment in an urban setting.

Jamie P Morano1, Mary R Walton, Alexei Zelenev, R Douglas Bruce, Frederick L Altice.   

Abstract

Despite its benefit for treating active tuberculosis, directly observed therapy (DOT) for latent tuberculosis infection (LTBI) has been largely understudied among challenging inner city populations. Utilizing questionnaire data from a comprehensive mobile healthcare clinic in New Haven, CT from 2003 to July 2011, a total of 2,523 completed tuberculin skin tests (TSTs) resulted in 356 new LTBIs. Multivariate logistic regression correlated covariates of the two outcomes (a) initiation of isoniazid preventative therapy (IPT) and (b) completion of 9 months of IPT. Of the 357 newly positive TSTs, 86.3 % (n = 308) completed screening chest radiographs (CXRs): 90.3 % (n = 278) were normal, and 0.3 % (n = 1) had active tuberculosis. Of those completing CXR screening, 44.0 % (n = 135) agreed to IPT: 69.6 % (n = 94) selected DOT, and 30.4 % (n = 41) selected self-administered therapy (SAT). Initiating IPT was correlated with undocumented status (AOR = 3.43; p < 0.001) and being born in a country of highest and third highest tuberculosis prevalence (AOR = 14.09; p = 0.017 and AOR = 2.25; p = 0.005, respectively). Those selecting DOT were more likely to be Hispanic (83.0 vs 53.7 %; p < 0.0001), undocumented (57.4 vs 41.5 %; p = 0.012), employed (p < 0.0001), uninsured (p = 0.014), and have stable housing (p = 0.002), no prior cocaine or crack use (p = 0.013) and no recent incarceration (p = 0.001). Completing 9 months of IPT was correlated with no recent incarceration (AOR 5.95; p = 0.036) and younger age (AOR 1.03; p = 0.031). SAT and DOT participants did not significantly differ for IPT duration (6.54 vs 5.68 months; p = 0.216) nor 9-month completion (59.8 vs 46.3 %; p = 0.155). In an urban mobile healthcare sample, screening completion for LTBI was high with nearly half initiating IPT. Undocumented, Hispanic immigrants from high prevalence tuberculosis countries were more likely to self-select DOT at the mobile outreach clinic, potentially because of more culturally, linguistically, and logistically accessible services and self-selection optimization phenomena. Within a diverse, urban environment, DOT and SAT IPT models for LTBI treatment resulted in similar outcomes, yet outcomes were hampered by differential measurement bias between DOT and SAT participants.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23728822      PMCID: PMC3781590          DOI: 10.1007/s10900-013-9704-y

Source DB:  PubMed          Journal:  J Community Health        ISSN: 0094-5145


  23 in total

1.  Prevalence and risk factors for positive tuberculin skin tests among active drug users at a syringe exchange program.

Authors:  N Salomon; D C Perlman; P Friedmann; V Ziluck; D C Des Jarlais
Journal:  Int J Tuberc Lung Dis       Date:  2000-01       Impact factor: 2.373

2.  Effectiveness of a mobile medical van in providing screening services for STDs and HIV.

Authors:  Jon Liebman; Mary Pat Lamberti; Frederick Altice
Journal:  Public Health Nurs       Date:  2002 Sep-Oct       Impact factor: 1.462

3.  Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication.

Authors:  R Douglas Bruce; Julie Eiserman; Angela Acosta; Ceilia Gote; Joseph K Lim; Frederick L Altice
Journal:  Am J Drug Alcohol Abuse       Date:  2012-01-13       Impact factor: 3.829

4.  Trends in tuberculosis - United States, 2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-03-23       Impact factor: 17.586

5.  Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community - a potential conduit to improved HIV treatment outcomes.

Authors:  Ali Shabahang Saber-Tehrani; Sandra A Springer; Jingjun Qiu; Maua Herme; Jeffrey Wickersham; Frederick L Altice
Journal:  Contemp Clin Trials       Date:  2011-11-12       Impact factor: 2.226

6.  Missed opportunities to prevent tuberculosis in foreign-born persons, Connecticut, 2005-2008.

Authors:  A Guh; L Sosa; J L Hadler; M N Lobato
Journal:  Int J Tuberc Lung Dis       Date:  2011-08       Impact factor: 2.373

7.  Knowledge of tuberculosis among drug users. Relationship to return rates for tuberculosis screening at a syringe exchange.

Authors:  N Salomon; D C Perlman; P Friedmann; M P Perkins; V Ziluck; D C Jarlais; D Paone
Journal:  J Subst Abuse Treat       Date:  1999-04

8.  Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.

Authors:  Linda Weiss; Julie Netherland; James E Egan; Timothy P Flanigan; David A Fiellin; Ruth Finkelstein; Frederick L Altice
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

9.  Adherence to hepatitis B virus vaccination at syringe exchange sites.

Authors:  Frederick L Altice; Robert D Bruce; Mary R Walton; Marta I Buitrago
Journal:  J Urban Health       Date:  2005-03-03       Impact factor: 3.671

10.  Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication.

Authors:  Frederick L Altice; Jo Anne Mezger; John Hodges; Robert D Bruce; Adrian Marinovich; Mary Walton; Sandra A Springer; Gerald H Friedland
Journal:  Clin Infect Dis       Date:  2004-06-01       Impact factor: 9.079

View more
  8 in total

1.  Accessibility and utilization patterns of a mobile medical clinic among vulnerable populations.

Authors:  Britton A Gibson; Debarchana Ghosh; Jamie P Morano; Frederick L Altice
Journal:  Health Place       Date:  2014-05-21       Impact factor: 4.078

2.  Latent tuberculosis infection screening in foreign-born populations: a successful mobile clinic outreach model.

Authors:  Jamie P Morano; Alexei Zelenev; Mary R Walton; R Douglas Bruce; Frederick L Altice
Journal:  Am J Public Health       Date:  2014-06-12       Impact factor: 9.308

3.  Compliance with Tuberculosis Screening in Irregular Immigrants.

Authors:  Francesca Bonvicini; Silvia Cilloni; Rossano Fornaciari; Carmen Casoni; Cristina Marchesi; Marina Greci; Lucia Monici; Fausto Nicolini; Marco Vinceti
Journal:  Int J Environ Res Public Health       Date:  2018-12-23       Impact factor: 3.390

4.  Rapid Deployment of a Mobile Medical Clinic During the COVID-19 Pandemic: Assessment of Dyadic Maternal-Child Care.

Authors:  Julia Rosenberg; Leslie Sude; Mariana Budge; Daisy León-Martínez; Ada Fenick; Frederick L Altice; Mona Sharifi
Journal:  Matern Child Health J       Date:  2022-07-28

5.  Effect of varenicline directly observed therapy versus varenicline self-administered therapy on varenicline adherence and smoking cessation in methadone-maintained smokers: a randomized controlled trial.

Authors:  Shadi Nahvi; Tangeria R Adams; Yuming Ning; Chenshu Zhang; Julia H Arnsten
Journal:  Addiction       Date:  2020-10-13       Impact factor: 6.526

Review 6.  Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review.

Authors:  Anke L Stuurman; Marije Vonk Noordegraaf-Schouten; Femke van Kessel; Anouk M Oordt-Speets; Andreas Sandgren; Marieke J van der Werf
Journal:  BMC Infect Dis       Date:  2016-06-08       Impact factor: 3.090

7.  Initiation and completion rates for latent tuberculosis infection treatment: a systematic review.

Authors:  Andreas Sandgren; Marije Vonk Noordegraaf-Schouten; Femke van Kessel; Anke Stuurman; Anouk Oordt-Speets; Marieke J van der Werf
Journal:  BMC Infect Dis       Date:  2016-05-17       Impact factor: 3.090

8.  A Step toward Tuberculosis Elimination in a Low-Incidence Country: Successful Diagnosis and Treatment of Latent Tuberculosis Infection in a Refugee Clinic.

Authors:  Elissa Rennert-May; Elisabeth Hansen; Toktam Zadeh; Valerie Krinke; Stan Houston; Ryan Cooper
Journal:  Can Respir J       Date:  2016-02-24       Impact factor: 2.409

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.